Parallel Fluidics, a company developing on-demand microfluidic manufacturing solutions with applications in IVF and other life science fields, has secured $7 million in seed funding. The round was led by J2 Ventures with participation from 8VC and Praxis.
The company’s technology is already making waves in the fertility sector. Overture Life, a startup focused on simplifying IVF procedures, is utilizing Parallel Fluidics’ latest innovation, the MV-2 microvalve, to enhance flow control in their next-generation IVF systems.
“In order to provide advanced care in fertility treatments such as IVF, precise fluid control and the ability to manage sensitive biological samples without being wasteful are critical,” explained Lionel Matthys, Chief Product Officer at Overture Life. “Solutions like Parallel Fluidics’ microfluidic systems are filling that gap with their microvalves and enabling faster, more reliable processes that can help us enhance patient outcomes and drive innovation in reproductive medicine.”
The global microfluidics market, currently valued at $32 billion, is expected to reach $117.13 billion by 2031. The technology enables scientific tests to run at microscopic scales, allowing life science companies to achieve higher precision, speed, and throughput.
“Scientists and engineers developing the next breakthrough life science technology shouldn’t be forced to reinvent the wheel when it comes to microfluidic systems,” said Jon Bronson, PhD, Managing Partner and co-founder of J2 Ventures. “With clients including academic labs, venture-backed startups and large biotech companies, Parallel Fluidics is making a huge impact with its on-demand microfluidic manufacturing services. Their products eliminate the common development risks, and accelerate the timeline from concept to launch by delivering production-ready devices in as little as three days – a true game changer for time-sensitive, cost-effective R&D.”
The funding will help drive the growth of the company’s on-demand design and manufacturing platform, expand its hardware and software solutions, and commercialize its new product, MV-2. This microvalve enables products to work at the point-of-care, such as doctor’s offices, clinics, or hospitals, instead of only in laboratory environments.
“While more life science products are built with microfluidics, scientific teams have historically struggled with engineering and manufacturing challenges unrelated to their novel technology, such as flow control, automation, and the chip-to-world interface,” said Josh Gomes, CEO and co-founder of Parallel Fluidics. “At Parallel Fluidics, we are on a mission to help scientific teams build scalable and reliable products to identify diseases faster and develop more effective medicines. With the new funding, we’ll be able to scale up our on-demand manufacturing service, expand our hardware library, and develop new design and analytics software to power the next generation of life science tools.”
